书目名称 | Regulating Pharmaceutical Prices in India |
副标题 | Policy Design, Imple |
编辑 | Ajay Bhaskarabhatla |
视频video | |
概述 | Based on rigorous analysis of comprehensive time-series data on the industry.Written for administrators, policy makers, as well as researchers dealing with regulation and pharma industry.Presents ways |
丛书名称 | India Studies in Business and Economics |
图书封面 |  |
描述 | .This book presents an extensive study on the effectiveness of recent regulations on pharmaceutical prices in India, exploring the weaknesses in the design and implementation of pharmaceutical price controls and investigating what can be done to fix the broken system..In addition, it examines the extent to which essential medicines are actually made affordable by price controls. The book argues that companies make the pharmaceutical price control regime largely ineffective by coordinating to increase pre-regulation prices; by diversifying horizontally away from the regulated markets and increasing prices in the unregulated markets; by manipulating trade margins; and by refusing to comply with the regulation because the penalties remains negligible..The book draws on extensive empirical research involving India’s 2013 Drug Price Control Order and widely-used medicines such as paracetamol and metformin to illustrate how firms have weakened regulation. It argues that theregulatory regime can be strengthened by using systematic analysis of product- and region-level data in the Indian pharmaceutical industry, and by screening for the strategies that firms currently employ to circumvent |
出版日期 | Book 2018 |
关键词 | Company Law; Drug price Control; FDI; Generic Drugs; Indian Bureaucracy; Medicine Practice; Pharmaceutical |
版次 | 1 |
doi | https://doi.org/10.1007/978-3-319-93393-1 |
isbn_softcover | 978-3-030-06652-9 |
isbn_ebook | 978-3-319-93393-1Series ISSN 2198-0012 Series E-ISSN 2198-0020 |
issn_series | 2198-0012 |
copyright | Springer International Publishing AG, part of Springer Nature 2018 |